Robust analysis of a mixed-effect model for a multicenter clinical trial
- PMID: 12146718
- DOI: 10.1081/bip-120005738
Robust analysis of a mixed-effect model for a multicenter clinical trial
Abstract
We consider a multicenter clinical trial with treatments as fixed effects and centers and residuals as bivariate and univariate random effects, respectively. There exist situations where it is difficult to justify the conventional normality assumptions for the random components. Following Khatri and Patel (Commun. Stat.-Theory Methods 1992, 21, 21-39), we propose the weighted least-squares (WLS) method and two bootstrap methods, percentile and BCa, that are robust to the departure from normality. Through a simulation study, we compare WLS and bootstrap confidence intervals for the treatment difference. While all three methods give confidence intervals with desired coverage rates, the WLS method gives shorter intervals. We also propose a bootstrap method that is robust to outliers. A numerical example is given to illustrate the methodology.
Similar articles
-
Five interval estimators of the risk difference under stratified randomized clinical trials with noncompliance and repeated measurements.J Biopharm Stat. 2013;23(4):756-73. doi: 10.1080/10543406.2013.792828. J Biopharm Stat. 2013. PMID: 23786643
-
Test homogeneity of odds ratio in a randomized clinical trial with noncompliance.J Biopharm Stat. 2009 Sep;19(5):916-32. doi: 10.1080/10543400903105497. J Biopharm Stat. 2009. PMID: 20183452
-
Construction of confidence intervals for the risk differences in stratified design with correlated bilateral data.J Biopharm Stat. 2019;29(3):446-467. doi: 10.1080/10543406.2019.1579222. Epub 2019 Apr 1. J Biopharm Stat. 2019. PMID: 30933654
-
Review of rank-based procedures for multicenter clinical trials.J Biopharm Stat. 2013;23(6):1207-27. doi: 10.1080/10543406.2013.834919. J Biopharm Stat. 2013. PMID: 24138428 Review.
-
Weighted evidence approach of bridging study.J Biopharm Stat. 2012 Sep;22(5):952-65. doi: 10.1080/10543406.2012.701580. J Biopharm Stat. 2012. PMID: 22946942 Review.
Cited by
-
The analysis of multinational cost-effectiveness data for reimbursement decisions: a critical appraisal of recent methodological developments.Pharmacoeconomics. 2010;28(12):1079-96. doi: 10.2165/11537760-000000000-00000. Pharmacoeconomics. 2010. PMID: 21080734
MeSH terms
LinkOut - more resources
Full Text Sources